首页» English» Professor»
 
Prof. Qi Xianrong
发布日期：2011-11-03 浏览次数： 字号：[ 大 中 小 ]

 

Welcome to the Qi Laboratory

Department of Pharmaceutics

School of Pharmaceutical Sciences

Peking University

 

Contact Us:

Xian-Rong Qi, Ph.D and Professor

Department of Pharmaceutics

School of Pharmaceutical Sciences

Health Science Center, Peking University

38 Xueyuan Road, Haidian District

Beijing, 100191, P.R. China, 100191

Tel/Fax: 86-10-82801584

E-mail: qixr@bjmu.edu.cn

 

Research Interests:

Controlled drug/gene targeting delivery system

Nanotechnology and biotechnology

 

Xian-Rong Qi is a Professor of the School of Pharmaceutical Sciences, Peking University, a commissionerof the Committee of Pharmaceutics, Chinese Pharmaceutical Association (CPA). She received her bachelor degree from Beijing Medical University in 1987, and Ph.D. degree from Hoshi University (Japan) in 1997.

Professor Qi has received several international and internal honors and awards, including the Nagai Foundation (1995 and 2009), Science Progress Award of Beijing Government (2001), Science Progress Award of Ministry of Education (1995，2000，2003, 2009 and 2012, respectively), Science and Technology Award of Chinese Association of Integrative Medicine (2007), etc. Professor Qi is the principle investigator for series grants, including the Grant for the Returned Overseas Scholars of Ministry of Education, Natural Science Foundation of China Grant, Key Grant of Ministry of Science and Technology, Natural Science Foundation of Beijing, Research Fund for the Doctoral Program of Higher Education of China,etc. Professor Qi is the reviewer/referee of the National Spark Program, the National New Products Program, and China International Science and Technology Cooperation Program, etc. She has published more than 100 research papers, and 19 textbooks.

 


 

Selected Publications：

  1. D.S. Liang, H.T. Su, Y.J. Liu, A.T. Wang, X.R. Qi*. Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers. Biomaterials 2015, 71, 11-23.
  2. W. Gao , T. Meng , N. Shi , H. Zhuang , Z. Yang , X.R. Qi*. Targeting and microenvironment responsive lipid nanocarrier for the enhancement of Targeting and Microenvironment-Responsive Lipid Nanocarrier for the Enhancement of Tumor Cell Recognition and Therapeutic Efficiency. Adv. Healthc. Mater. 2015, 4, 748–759.
  3. A. Wang, D. Liang, Y. Liu, X.R. Qi*. Roles of ligand and TPGS of micelles in regulating internalization, penetration and accumulation against sensitive or resistant tumor and therapy for multidrug resistant tumors. Biomaterials 2015, 53, 160-172.
  4. D. Dong, W. Gao, Y. Liu, X.R. Qi*. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer. Cancer Letters 2015, 359, 178–186.
  5. L. Sun, Y.J. Liu, Z.Z. Yang, X.R. Qi*. Tumor specific delivery with redox-1 triggered mesoporous silica nanoparticles inducing neovascularization suppression and vascular normalization. RSC Advances, 2015, 5, 55566-55578.
  6. D.S. Liang, H.T. Su, Y.J Liu, A.T. Wang, X.R. Qi*. Enhance Cancer Cell Recognition and Overcome Drug Resistance Using Hyaluronic Acid and α-Tocopheryl Succinate Based Multifunctional Nanoparticles. Mol. Pharmaceutics, 2015, 12 (6), 2189–2202.
  7. Z.Z. Yang, J.Q. Li, Z.Z. Wang, D.W. Dong, X.R. Qi*. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 2014, 35, 5226-5239.
  8. Z. Yang, B. Xiang, D. Dong, Z. Wang, J. Li, X.R. Qi*. Dual receptor-specific peptides modified liposomes as VEGF siRNA vector for tumor-targeting therapy. Current Gene Therapy. 2014, 4,289-299.
  9. N.Q. Shi*, X.R. Qi*, B Xiang, Y Zhang. A survey on“Trojan Horse”peptides Opportunities, issues and controlled entry to“Troy”.J. Control. Release 2014, 194, 53–70.
  10. K. Wu, Z.Z. Wang, D. Liu, X.R. Qi*. Pharmacokinetics, brain distribution, release and blood–brain barrier transport of Shunaoxin pills. J. Ethnopharmacol. 2014, 151, 1133-1140.
  11. W. Gao, B. Xiang, T. Meng, F. Liu, X.R. Qi *. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials. 2013, 34: 4137-4149.
  12. D. Dong, B. Xiang,W. Gao, Z. Yang, J. Li, X.R. Qi *. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. Biomaterials. 2013, 34: 4849-4859.
  13. B Xiang, D Dong, N Shi, W Gao, Z Yang, Y Cui, D Cao, XR Qi*. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials. 2013, 34: 6976-6991.
  14. D Dong, S Tong, XR Qi*. Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers. J. Biomed. Mater. Res. 2013, 101A, 1336-1344.
  15. ZZ Yang, YQ Zhang, ZZ Wang, K Wu, JN Lou, XR Qi*. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int. J. Pharm. 2013, 452, 344– 354.
  16. ZZ Yang, ZZ Wang, K Wu, XR Qi*. Tissue Distribution and Pharmacodynamics of Rivastigmine after Intranasal and Intravenous Administration in Rats. Current Alzheimer Res. 2012, 9(3), 315-325.
  17. SW Tong, B Xiang, DW Dong, XR Qi*. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles.Int. J. Pharm.2012, 434, 413– 419.
  18. NQ Shi, W Gao, B Xiang, XR Qi*. Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage. Int. J. Nanomed.2012, 7, 1613–1621.
  19. ZX Lv, LT Liu, XR Qi*. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int. J. Nanomed. 2011, 6, 1661-1673.
  20. DX Ma, NQ Shi, XR Qi*. Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells. Int. J. Pharm. 2011,419（1-2）, 200-208.
  21. W zhao, S Zhuang, XR Qi*. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes.Int. J. Nanomed. 2011, 6, 3087-3098.
  22. Y Li, XR Qi*, Y Maitani, T Nagai. PEG–PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations. Nanotechnology 2009, 20, 055106.
  23. WX Ding, T Izumisawa, Y Hattori, XR Qi, D Kitamoto, Y Maitani. Non-ionic surfactant modified cationic liposomes mediated gene transfection in vitro and in the mouse lung. Biol Pharm Bull 2009, 32(2), 311-315.
  24. WX Ding, Y Hattori, XR Qi, Kitamoto Dai; Y Maitani. Surface properties of lipoplexes modified with mannosylerythritol lipid-A and tween 80 and their cellular association. Chem Pharm Bull 2009, 57(2), 138-143.
  25. HL Ma, XR Qi*, WX Ding, Y Maitani, T Nagai. Magnetic targeting after femoral artery administration and biocompatibility assessment of superparamagnetic iron oxide nanoparticles. J Biomed Mater Res 2008, 84A(3), 598-606.
  26. HL Ma, YF Xu, XR Qi*, Y Maitani, T Nagai. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers.Int J Pharm 2008, 354 (1-2):217–226.
  27. HL Ma, XR Qi*, Y. Maitani, T. Nagai. Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int. J. Pharm. 2007, 333:177–186.
  28. Y Zhang, XR Qi*, Y Gao, L Wei, Y Maitani, T Nagai. Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J Control Release 2007, 117, 281–290.
  29. WX Ding, XR Qi*, Q Fu, SX Piao. The pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. Drug Delivery 2007, 14, 101-104.
  30. XR Qi*, Y Yan, XD Ma, TY Li, XY Nie, BB Yang. Development of a local vasodilator delivery system using fibrin glue to prevent arterial graft from spasm. J Biomed Mater Res 2007,82A(1), 139–144.
  31. L Feng，XR Qi*, XJ Zhou, Y Maitani, SC Wang, Y Jiang, T Nagai. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release 2006, 112(1), 35-42.
  32. XR Qi*, WW Yan, J Shi. Hepatocytes targeting of cationic liposomes modified with soybean sterylglucoside and polyethylene glycol. World J Gastroenterol 2005, 11(32), 4947-4952.
  33. WX Ding, XR Qi*, P Li, Y Maitani, T Nagai. Cholesteryl hemisuccinate as a membrane stabilizer in dipalmitoylphosphatidylcholine liposomes containing saikosaponin-D. Int J Pharm 2005, 300, 38–47.
  34. J Shi, WW Yan. XR Qi*, Y Maitani, T Nagai. Characteristics and biodistribution of soybean sterylglucoside and polyethylene glycol-modified cationic liposomes and their complexes with antisense oligodeoxynucleotide. Drug delivery 2005, 12(6), 349-356.
  35. CJ Xiao, XR Qi*, Y Maitani, T Nagai. Sustained-release cisplatin from multivesicular liposomes:potentiation of antitumor efficacy against S180 murine carcinoma. J Pharm Sci 2004, 93(7), 1718-1724.
  36. XR Qi*, MH Liu, HY Liu,Y Maitani, T Nagai. Topical econazole delivery using liposomal gel. STP Pharm Sci 2003, 13(4), 241-245.
  37. SH Hwang, Y Maitani, XR Qi, K Takayama, Tsuneji Nagai. Remote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods.Int J Pharm 1999, 179, 85-95.
  38. K Shimizu, XR Qi, Y Maitani, M Yoshii, K Kawano, K Takayama, T Nagai. Targeting of soybean-derived sterylglucoside liposomes to liver tumors in rat and mice models.Biol Pharm Bull 1998, 21(7), 741-746.
  39. XR Qi, Y Maitani, T Nagai, SL Wei. Comparative pharmacokinetics and antitumor efficacy of doxorubicin encapsulated in soybean-derived sterols and poly(ethylene glycol) liposomes in mice. Int J Pharm 1997,146, 31-39.
  40. XR Qi, Y Maitani, T Nagai. Relation of rigidity of membrane and stability of dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols prepared by reverse-phase evaporation vesicle method. Chem Pharm Bull 1996, 44(1), 237-240.
  41. XR Qi, Y Maitani, T Nagai. Effect of soybean-derived sterols on the in vitro stability and the blood circulation of liposomes in mice.Int J Pharm 1995, 114, 33-41.
  42. XR Qi, Y Maitani, T Nagai. Rates of systemic degradation and reticuloendothelial system uptake of calcein in the dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols in mice. Pharm Res 1995, 12(1), 49-52.
  43. XR Qi, Y Maitani, N Shimoda, K Sakaguchi, T Nagai. Evaluation of liposomal erythropoietin prepared with reverse-phase evaporation vesicle method by subcutaneous administration in rats. Chem Pharm Bul 1995, 43(2), 295-299.
  44. Y Maitani, M Hazama, H Tojo, XR Qi, T Nagai. Effects of orally administered liposomes with soybean-derived sterols and their glucosides on rat body weight. Biol Pharm Bull 1995, 18(11), 1551-1555.
  45. XR Qi, Y Maitani, T Nagai. Relation of rigidity of membrane and stability of dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols prepared by reverse-phase evaporation vesicle method.Chem Pharm Bull 1996, 44(1), 237-240.



打印本页 关闭窗口